Advances in β-Thalassemia Gene Therapy: CRISPR/Cas Systems and Delivery Innovations
Open Access
Abstract
β-thalassemia is an inherited blood disorder caused by mutations in the β-globin (HBB) gene, leading to reduced or absent β-globin production, resulting in chronic anemia. While current therapies, including blood transfusions and hematopoietic stem cell transplantation, offer symptomatic relief, they are limited by complications and their limited accessibility. CRISPR-based gene editing technologies provide new therapeutic avenues by enabling the precise correction of HBB mutations or the reactivation of fetal hemoglobin (HbF) through the targeting of regulatory elements such as BCL11A. These approaches have shown promising preclinical and clinical outcomes. However, efficient and safe delivery remains a major challenge. Viral vectors offer high efficiency but raise concerns about immunogenicity and insertional mutagenesis, whereas non-viral systems such as lipid nanoparticles and engineered exosomes offer lower toxicity and modularity but face targeting limitations. This review highlights recent progress in CRISPR-based therapies for β-thalassemia and emerging delivery strategies to enhance clinical translation.Keywords
Funding Information
- National Natural Science Foundation of China (32200691)
- Bureau of Science and Technology of Guangzhou Municipality (2023A04J0720)
- Guizhou Medical University (J (2024)065)
- Higher Education Institutions Scientific and Technological Innovation Team of Guizhou Province (qianjiaoji2023-068)
This publication has 105 references indexed in Scilit:
- RETRACTED: Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleasesCancer Genetics, 2025
- CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemiaHuman Genetics, 2023
- Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cellsHuman Genetics, 2023
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022
- Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR2022
- Current status of beta‐thalassemia and its treatment strategiesMolecular Genetics & Genomic Medicine, 2021
- Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA RepairStem Cells, 2018
- Aptamer-based targeted therapyAdvanced Drug Delivery Reviews, 2018
- Molecular basis of α-thalassemiaBlood Cells, Molecules, and Diseases, 2018
- Lentiviral Vectors in Gene Therapy: Their Current Status and Future PotentialArchivum Immunologiae et Therapiae Experimentalis, 2010